FIELD: medicine.
SUBSTANCE: invention relates to a pregnenolone derivative of formula (I) in the treatment of cognitive disorders, where the cognitive disorder is associated with age-related cognitive decline; or the cognitive disorder is a disorder associated with neurological development, which refers to patients diagnosed with a pathology selected from Down syndrome or fragile X syndrome; and wherein the said compound is administered to a subject at a dose of 1 μg to 1,000 mg.
EFFECT: treatment of cognitive disorders associated with age-related cognitive decline or in patients with Down syndrome or fragile X syndrome.
3 cl, 14 dwg, 3 tbl, 5 ex
Formula (I)
| Title | Year | Author | Number |
|---|---|---|---|
| 3-β(4-METHOXYBENZYLOXY)PREGN-5-EN-20-ONE FOR USE IN TREATMENT OF DISORDERS RELATED TO CONSUMPTION OF CANNABINOIDS | 2019 |
|
RU2788004C2 |
| CB1 RECEPTOR ANTAGONISTS | 2012 |
|
RU2593751C2 |
| DONECOPRID AS A NEUROPROTECTIVE AGENT IN THE TREATMENT OF NEURODEGERATIVE DISEASES | 2019 |
|
RU2800802C2 |
| APPLICATION OF ACTIVE PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | 2011 |
|
RU2563167C2 |
| LIGUSTILIDE DERIVATIVES FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | 2007 |
|
RU2462462C2 |
| METHODS FOR IMPROVEMENT OF MEMORY AND COGNITIVE FUNCTION AND TREATMENT OF MEMORY DISORDERS AND COGNITIVE DISORDERS | 2018 |
|
RU2785125C2 |
| LIGAND WITH WIDE RANGE OF SIMULTANEOUS RECEPTOR ACTIVITY, PHARMACEUTICAL COMPOSITION, METHOD OF PREPARING SAID COMPOSITION AND MEDICINAL AGENT | 2008 |
|
RU2374245C1 |
| DERIVATIVES OF PREGNENOLONE | 2013 |
|
RU2667065C2 |
| METHOD FOR IMPROVING FUNCTIONAL SYNAPTIC CONNECTIVITY | 2013 |
|
RU2667968C2 |
| USING CANNABINOIDS COMBINED WITH ANTIPSYCHOTIC DRUG PREPARATION | 2008 |
|
RU2503448C2 |
